Eupraxia Pharmaceuticals Inc (EPRX) - Total Liabilities
Based on the latest financial reports, Eupraxia Pharmaceuticals Inc (EPRX) has total liabilities worth CA$5.43 Million CAD (≈ $3.93 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Eupraxia Pharmaceuticals Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Eupraxia Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See EPRX working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Eupraxia Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Eupraxia Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hainan Yedao Group Co Ltd
SHG:600238
|
China | CN¥742.70 Million |
|
ITAFOS INC. ON
F:82E
|
Germany | €378.91 Million |
|
Suzhou Fushilai Pharmaceutical Co. Ltd.
SHE:301258
|
China | CN¥211.52 Million |
|
Ve Wong Corp
TW:1203
|
Taiwan | NT$3.14 Billion |
|
enCore Energy Corp.
V:EU
|
Canada | CA$172.04 Million |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$2.36 Billion |
|
Unico Silver Ltd
AU:USL
|
Australia | AU$4.26 Million |
|
Mobiltel Iletisim Hizmetleri Sanayi ve Ticaret AS
IS:MOBTL
|
Turkey | TL3.83 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Eupraxia Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EPRX stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 23.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eupraxia Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eupraxia Pharmaceuticals Inc (2017–2024)
The table below shows the annual total liabilities of Eupraxia Pharmaceuticals Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$4.46 Million ≈ $3.23 Million |
-82.53% |
| 2023-12-31 | CA$25.55 Million ≈ $18.48 Million |
+76.03% |
| 2022-12-31 | CA$14.51 Million ≈ $10.50 Million |
+24.36% |
| 2021-12-31 | CA$11.67 Million ≈ $8.44 Million |
-49.52% |
| 2020-12-31 | CA$23.12 Million ≈ $16.72 Million |
+7.94% |
| 2019-12-31 | CA$21.42 Million ≈ $15.49 Million |
+49.30% |
| 2018-12-31 | CA$14.34 Million ≈ $10.38 Million |
+1849.47% |
| 2017-12-31 | CA$735.82K ≈ $532.28K |
-- |
About Eupraxia Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unm… Read more